NCT02028364View on ClinicalTrials.gov

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 12, 2014

Primary Completion Date

July 6, 2021

Study Completion Date

August 9, 2021

Conditions
Breast Cancer
Interventions
DRUG

Everolimus

10mg orally daily

DRUG

Exemestane

25mg orally daily

Trial Locations (5)

1000

institut Jules Bordet, Brussels

1200

Cliniques Universtaires Saint-Luc, Brussels

3000

UZ Leuven, Leuven

5000

Clinique et Maternité Sainte Elisabeth, Namur

7000

CHU Ambroise Paré, Mons

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Jules Bordet Institute

OTHER